Raising the bar on first-line immunotherapy in lung cancer
Mené sur 77 patients atteints d'un cancer du poumon non à petites cellules de stade avancé, cet essai de phase I évalue la toxicité et l'activité antitumorale d'un traitement de première ligne combinant nivolumab et ipilimumab
The advent of immunotherapies has led to a major shift in the treatment of advanced non-small-cell lung cancer (NSCLC). In the past 18 months, three programmed death-1 (PD-1) and PD ligand 1 (PD-L1) checkpoint inhibitors—nivolumab, pembrolizumab, and atezolizumab—have received US Food and Drug Administration approval for second-line treatment of advanced NSCLC,1–4 spurring numerous efforts to assess immunotherapies in the front-line setting. For example, findings from KEYNOTE-024 showed superior efficacy and overall survival of pembrolizumab compared with platinum-doublet chemotherapy in patients with untreated NSCLC with a high level of PD-L1 expression (≥50% of tumour cells).
The Lancet Oncology , commentaire, 2015